Amprenavir/ritonavir

Boosted PIs Are More Forgiving of Non Adherence than Non-boosted PIs or NNRTI - 2/28/06

Results of Salvage Therapy with Ritonavir-boosted Amprenavir and Ritonavir-boosted Fosamprenavir - 10/12/05

Tipranavir/ritonavir Demonstrates Superior Response to Lopinavir/ritonavir, Amprenavir/ritonavir or Saquinavir/ritonavir in PI-experienced Patients - 8/08/05

Amprenavir or Fosamprenavir Plus Ritonavir in HIV Infection: Pharmacology, Efficacy and Tolerability Profile - 3/16/05

96-Week Lipids and Anthropometrics in Patients Receiving Initial Therapy with Abacavir + Lamivudine Combined with Efavirenz, Amprenavir/Ritonavir or Stavudine: The Class Study  - 08/09/04

Efficacy, Safety and Predictive Factors of Virological Success of a Boosted Amprenavir-based Salvage Regimen - 07/30/04

Baseline Viral Load and the Number of PI Mutations Are Associated with the Virological Outcome of Ritonavir-boosted Amprenavir Regimens - 07/26/04

Initial Therapy with NRTIs Abacavir + Lamivudine Combined with NNRTI Efavirenz, PIs Amprenavir/Ritonavir or NRTI Stavudine  - 07/21/04

Lopinavir Significantly Decreases the Amprenavir Concentration During Amprenavir and Lopinavir/Ritonavir Combination Therapy - 4/09/04

Pharmacokinetics of Agenerase Given Once or Twice a Day When Combined with Reyataz in Heavily Pre-treated HIV Patients 02/04/04

Pharmacologic Enhancement in Protease Inhibitor-based HAART: The Role of Ritonavir 02/02/04

Effect of Lopinavir on Agenerase (amprenavir) Concentrations Boosted by Norvir (ritonavir) 01/23/04

In vitro-in vivo Model for Evaluating the Antiviral Activity of Agenerase (amprenavir) in Combination with Norvir (ritonavir) 01/23/04

Atazanavir/ritonavir

No Significant Body Composition Differences between Patients Treated with Atazanavir vs Atazanavir/ritonavir  - 3/20/07

Body Composition Changes in ART-naive Subjects Treated with Atazanavir or Atazanavir/Ritonavir-based Once-daily HAART: 48-Week Computed Tomography and DEXA Data
D McGrath and others. Poster 804.  3/16/07

Once-daily boosted fosamprenavir (FPV/r) or atazanavir (ATV/r) with tenofovir (TDF)/emtricitabine (FTC) in antiretroviral naive HIV-1 infected patients: 24-week results from COL103952 (ALERT). 11/27/06

The safety and the effectiveness of antiretroviral therapy containing atazanavir/ritonavir (ATV/r) with or without tenofovir (TDF). 11/27/06

Acetaminophen pharmacokinetics and hepatic transaminases are unaffected on atazanavir/ritonavir coadministration. 11/27/06

Induction/maintenance strategy with atazanavir/ritonavir. 11/27/06

Lipids and lipoproteins in HIV-subjects treated with lopinavir/ritonavir (L) or atazanavir/ritonavir (A) based antiretroviral therapy. 11/27/06

Once-daily Boosted Fosamprenavir or Atazanavir in Treatment-naive Patients: The ALERT Study   10/06/06

Impact of Boosted vs Unboosted Atazanavir-based Regimens on the Lipid Profiles of HIV Positive Patients - 8/29/06

Atazanavir/Ritonavir versus Efavirenz: Retrospective Review of a Large US Cohort  - 8/22/06

Treatment with Atazanavir with or without Ritonavir Results in Clinically Important Improvements in Health-related Quality of Life  - 8/22/06

Economic and Clinical Impact of Using Atazanavir + Ritonavir versus Lopinavir/Ritonavir- 8/22/06

Once-daily Atazanavir/Ritonavir and Twice-daily Lopinavir/Ritonavir in HIV Patients with Multiple Virologic Failures: 96 week Results - 3/07/06

Boosted PIs Are More Forgiving of Non Adherence than Non-boosted PIs or NNRTI - 2/28/06

Darunavir/ritonavir

Efficacy and Safety of Darunavir/ritonavir at Week 48 in Treatment-experienced HIV Patients: Pooled Analysis of POWER 1 and 2 Trials  - 4/06/07

Darunavir/ritonavir Shows Safety and Superior Virological and Immunological Efficacy in Treatment-experienced Patients at 24 Weeks  - 3/30/07

Efficacy and Safety of Prezista/ritonavir in Treatment-experienced Patients: 24-week Results of the POWER 1 Study   2/20/07

Ritonavir-boosted Darunavir Does Not Produce Significant Pharmacokinetic Changes when Coadministered with Ranitidine or Omeprazole  1/12/07

[P28] TMC114/r has tolerability and efficacy benefits for treatment-experienced patients compared with control PIs: overview of the POWER trials 11/27/06

[P51] Cost-effectiveness of TMC114 (darunavir)/ritonavir compared with currently available protease inhibitors in treatment-experienced HIV patients 11/27/06

Darunavir Interactions with Lopinavir/Ritonavir, Contraceptives, and Erectile Dysfunction Drugs

MC114/r in treatment-experienced patients in power 1, 2 and 3: integrated analysis of laboratory parameters 10/17/06

TMC114 provides durable viral load suppression in treatment-experienced patients: POWER 1 and 2 combined week 48 analysis 10/17/06

TMC114/r is well tolerated by treatment-experienced patients in power 1, 2 and 3: integrated clinical safety analysis 10/17/06

Combination of TMC114/ritonavir and TMC125 in patients with multidrug resistant HIV 10/17/06

TMC114/r in treatment-experienced HIV patients in power 3: 24-week efficacy and safety analysis 10/17/06

Fosamprenavir/ritonavir


Safety and Antiviral Activity of Fosamprenavir/Ritonavir (FPV/RTV) QD Regimens in HIV-Infected Pediatric Subjects Ages 2 to 18 Years (48 week Interim Data, Study APV20003)
E G Chadwick and others. Poster 7196. Copyright GlaxoSmithKline. Used with permission, 2007.  3/16/07

Once-daily boosted fosamprenavir (FPV/r) or atazanavir (ATV/r) with tenofovir (TDF)/emtricitabine (FTC) in antiretroviral naive HIV-1 infected patients: 24-week 11/27/06 .

Fosamprenavir/ritonavir (FPV/r): decrease of liver enzymes in patients co-infected with hepatitis C 11/27/06

Success of an induction-maintenance strategy using boosted fosamprenavir plus zidovudine and

Fosamprenavir boosted with a single 100 mg capsule of ritonavir as part of a once daily first line regimen in naive patients 11/27/06

Sustained virologic and immunologic response over 180 weeks in antiretroviral therapy (ART)-naïve subjects receiving fosamprenavir/ritonavir (FPV/r) QD 11/27/06

Efficacy and safety of once-daily boosted fosamprenavir/ritonavir (FPV/r) with abacavir (ABC)/lamivudine (3TC) fixed dose combination in antiretroviral naive HIV-1 infected patients: 24-week results from COL100758| 11/27/06

A clinically validated mutation score for resistance to fosamprenavir/ritonavir 11/27/06

The KLEAN Study: FPV/r BID vs LPV/r BID + ABC/3TC QD in ART Naïve Subjects 48 Week analysis demonstrates rare resistance and non-inferiority (ppt slides)   - 9/29/06

Boosted Fosamprenavir vs Lopinavir/ritonavir in Antiretroviral-Naive Patients (KLEAN) - 9/22/06

The KLEAN Study: Fosamprenavir + Ritonavir versus Lopinavir/Ritonavir   - 8/18/06

Therapeutic Drug Monitoring of Boosted Tipranavir with and without Combination to Lopinavir or Fosamprenavir - 3/17/06

Boosted PIs Are More Forgiving of Non Adherence than Non-boosted PIs or NNRTI - 2/28/06

Indinavir/ritonavir

[P383] Pharmacokinetics (PK), safety, tolerability and efficacy of boosted saquinavir 500mg film coated tablets in a regimen of 1000/100mg bid plus 2 nucleoside analogues (NRTIs) in HIV+ pregnant women 11/27/06

[P378] Placental transfer of lopinavir, saquinavir, and ritonavir 11/27/06

[P293] Effect of boosted saquinavir on the pharmacokinetics and pharmacodynamics of racemic methadone in opiate-dependent patients on stable methadone maintenance therapy 11/27/06

[PL2.5] Saquinavir/r (SQV/r) BID vs lopinavir/r (LPV/r) BID plus emtricitabine/tenofovir (FTC/TDF) QD in ARV-naive HIV-1 infected patients: GEMINI Study 11/27/06

P271] Trough concentrations in HIV patients receiving boosted hard-gel capsules (HGC) and 500mg film-coated tablet (FCT) formulations of saquinavir 11/27/06

Lopinavir/Ritonavir (LPV/r) Plus Saquinavir Combination Compares Favorably to LPV/r Plus Nucleosides-containing Regimen- 1/13//06

Boosted PIs Are More Forgiving of Non Adherence than Non-boosted PIs or NNRTI - 2/28/06

A Comparison of Dyslipidemias Associated with Either Lopinavir/Ritonavir- or Indinavir/Ritonavir-based Antiretroviral Therapy - 2/11/05

Lopinavir/ritonavir

Efficacy and Impact on Lipids of Reduced Lopinavir/ritonavir Dosing   10/03/06

Boosted Lopinavir/Ritonavir plus Saquinavir without Additional Anti-HIV Therapy - 8/25/06

Selection of Protease Inhibitor-Resistance Mutations During Failure of Lopinavir/ritonavir Monotherapy  - 8/22/06

Boosted PIs Are More Forgiving of Non Adherence than Non-boosted PIs or NNRTI - 2/28/06

New Tablet Formulation of Lopinavir/Ritonavir Is Bioequivalent to the Capsule at a Dose of 800/200 mg. T Zhu and others. - 12/18/05

Comparative Safety and Anti-HIV Activity of a Dual Protease Inhibitor Regimen (Lopinavir/ritonavir + Saquinavir) versus a Nucleoside-Containing Regimen. D Cameron and others. - 12/18/05

Dual Boosted Saquinavir/Lopinavir/Ritonavir at 24 Weeks Is Safe and Potent in Nucleoside-pretreated Children - 10/17/05

Tipranavir/ritonavir Demonstrates Superior Response to Lopinavir/ritonavir, Amprenavir/ritonavir or Saquinavir/ritonavir in PI-experienced Patients - 8/08/05

Efficacy and Tolerability of a NRTI-sparing Combination of Lopinavir/Ritonavir and Efavirenz - 6/29/05

Pharmacokinetics of Once-daily Lopinavir/Ritonavir and the Influence of Dose Modifications - 6/22/05

Drug Resistance More Likely in NNRTI plus NRTI Regimens Compared with Ritonavir-boosted Protease Inhibitors - 4/25/05

Use of Lopinavir/Ritonavir in HIV-infected Patients Failing First-line Protease Inhibitor-based HAART - 4/20/05

Saquinavir (Invirase)/ritonavir

Boosted Lopinavir/Ritonavir plus Saquinavir without Additional Anti-HIV Therapy - 8/25/06

Boosted PIs Are More Forgiving of Non Adherence than Non-boosted PIs or NNRTI - 2/28/06

Comparative Safety and Anti-HIV Activity of a Dual Protease Inhibitor Regimen (Lopinavir/ritonavir + Saquinavir) versus a Nucleoside-Containing Regimen. D Cameron and others. - 12/18/05

Effect of Omeprazole on the Pharmacokinetics of Saquinavir 500 mg Formulation with Ritonavir - 12/05/05

Inter-individual Variability of Once Daily Ritonavir Boosted Saquinavir Pharmacokinetics in Thai and UK Patients - 10/24/05

Dual Boosted Saquinavir/Lopinavir/Ritonavir at 24 Weeks Is Safe and Potent in Nucleoside-pretreated Children - 10/17/05

Tipranavir/ritonavir Demonstrates Superior Response to Lopinavir/ritonavir, Amprenavir/ritonavir or Saquinavir/ritonavir in PI-experienced Patients - 8/08/05

Roche Distributes “Dear Healthcare Provider” Letter on Discontinuation of Fortovase-brand Saquinavir - 6/06/05

Saquinavir (Invirase; Fortovase): An Overview - 6/06/05

Roche Gains European Approval for More Potent Formulation of Saquinavir - 6/01/05

In Early 2006 Roche Will Voluntarily Discontinue Sale and Distribution of HIV Protease Inhibitor (PI) Fortovase - 5/20/05

Atazanavir Plus Ritonavir or Saquinavir Compared to Lopinavir/Ritonavir in Patients Experiencing Multiple Virological Failures - 4/11/05

Boosted Saquinavir Hard-gel (Invirase) Formulation Exposure in HIV Patients: Ritonavir 100 mg Once Daily Versus Twice Daily - 3/07/05

Roche Issues Drug Interaction Warning on Hepatocellular Toxicity in Healthy Volunteers Receiving TB Drug Rifampin and Saquinavir/Ritonavir - 2/09/05

Atazanavir/Saquinavir

Atazanavir with or without Ritonavir Shows High Rate of Virologic Response - 3/17/06

Atazanavir Plus Ritonavir or Saquinavir Compared to Lopinavir/Ritonavir in Patients Experiencing Multiple Virological Failures - 4/11/05

Tipranavir/ritonavir

Response of Treatment-Experienced Children to Tipranavir/ritonavir  - 3/16/07

Predictors of response to TPV/r in pediatric patients: results of BI1182.14/PACTG1051
J Salazaz and others. Poster 733.  3/16/07

Effects of tipranavir/ritonavir (TPV/r) on the activity of hepatic and intestinal cytochrome P450 3A4/5 and P-glycoprotein (P-gp): implications for drug interactions
M Vourvahis and others. Poster 563.  3/16/07

Efficacy of tipranavir oral solution co-administered with low dose ritonavir (TPV/r) is similar in all age groups of children and teenagers 11/27/06

Combined analysis of RESIST 96 week data: durability and efficacy of tipranavir/r in treatment experienced patients 11/27/06

Efficacy and safety of two doses of tipranavir/ritonavir versus lopinavir/ritonavir-based therapy in antiretroviral-naive patients: results of BI 1182.33 11/27/06

Lack of virologic response to the combination of tipranavir/ritonavir + enfuvirtide in treatment experienced HIV-infected persons with multi-drug resistant virus can be predicted by the presence of two or more of six mutations from five positions in protease 11/27/06

Genotypic resistance to tipranavir/ritonavir (TPV/r) in the Italian EAP BI 1182.16 study 11/27/06

Tipranavir genotypic inhibitory quotient predicts 24-week virological response to TPV-based salvage regimens 11/27/06

Limited cross-resistance to tipranavir in patients previously treated with two or more protease inhibitors 11/27/06

Better treatment response (TR) to tipranavir/r (TPV/r) compared to lopinavir/r (LPV/r) in patients with higher lopinavir (LPV) mutation scores 11/27/06

Liver Toxicity Associated with Ritonavir-boosted Tipranavir   10/03/06

96-week RESIST Data Show Boosted Tipranavir Produces Superior and Durable Treatment Response   9/29/06

48-Week Efficacy and Safety of Ritonavir-boosted Tipranavir in Children and Teenagers - 8/29/06

Impact of Prior PI Usage on Week 48 Responses to Tipranavir Boosted with Ritonavir   - 8/18/06

Tipranavir/Ritonavir Is More Effective against Protease Inhibitor (PI)-resistant Strains than Other Ritonavir-boosted PIs   - 8/18/06

Therapeutic Drug Monitoring of Boosted Tipranavir with and without Combination to Lopinavir or Fosamprenavir - 3/17/06